Project Grant F31DA062453

Award Date 6/12/25
Completion Date 11/30/27
Dollars Obligated $90K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $192,500 in funding to Wayne State University to conduct research on the effects of gestational fentanyl exposure on offspring development. The key objectives are to determine the impact of fentanyl exposure during pregnancy on offspring morbidity, mortality, developmental milestones, external morphology, brain volume, morphology, and...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
The National Institute on Drug Abuse (NIDA) awarded a $483,056 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Massachusetts Medical School to conduct research on the mechanisms linking opioid addiction, sleep, and circadian rhythms. The primary goals are to investigate the roles of the circadian transcription factor NPAS2 and dopamine D3 receptor signaling in the nucleus accumbens in controlling opioid craving and relapse behaviors. The...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating the effects of early-life cannabinoid exposure on the development of the prefrontal cortex and cognitive behaviors in mice. The total funding amount is $1,433,155, with the award period running from June 1, 2024 to March 31, 2029. The key objectives of this research project are to: 1) reveal the spatial and...
This federal Project Grant award, titled "Optimizing Developmental Outcomes in Early Childhood after Neonatal Opioid Withdrawal Syndrome," is funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $180,059 award to the Research Institute at Nationwide Children's Hospital aims to identify positive childhood experiences (PCEs) that can buffer the effects of adverse childhood experiences (ACEs) and promote optimal...
This $2,112,744 project grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to generate evidence about the incidence of drug-related morbidities and maternal mortality among people who use drugs during pregnancy and the postpartum period. The study will analyze data from a longitudinal hospital database spanning 17 states from 2017-2022 and a CDC maternal mortality database from 2018-2022 to determine spatiotemporal...
This Project Grant award of $3,011,183 from the National Institute on Drug Abuse (NIDA), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate the effects of maternal opioid use disorder (OUD) on the placenta-brain axis and associated neurocognitive outcomes in offspring. The University of Kentucky Research Foundation, the prime awardee, will utilize a systems biology approach to integrate phenotypic, functional, and genomic data from the...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...

THE IMPACT OF PERINATAL FENTANYL ON DOPAMINE NEURON CIRCUITRY AND BEHAVIOR - PROJECT SUMMARY USE OF ILLICIT SUBSTANCES HAS REACHED ENDEMIC LEVELS IN THE UNITED STATES WITH OVER 91,000 DEATHS DUE TO DRUG OVERDOSE OCCURRING IN 2020. THIS HAS LARGELY AFFECTED WOMEN OF CHILDBEARING AGE AS OPIOID USE DISORDER HAS MORE THAN QUADRUPLED AMONG PREGNANT WOMEN IN THE PAST 20 YEARS. BOTH CLINICAL AND PRECLINICAL STUDIES SHOW THAT OPIOID EXPOSURE DURING GESTATION CAN LEAD TO DEVELOPMENTAL DELAYS, COGNITIVE IMPAIRMENT, ANHEDONIA AND REDUCED MOTIVATION IN OFFSPRING. OPIOIDS INDUCE NEUROADAPTATIONS IN THE MESOLIMBIC DOPAMINE PATHWAY, WHICH IS LARGELY IMPLICATED IN REWARD. THE PATHWAY ORIGINATES IN THE VENTRAL TEGMENTAL AREA (VTA) WHERE DOPAMINE NEURONS PROJECT TO THE NUCLEUS ACCUMBENS (NAC). PROLONGED OPIOID USE HAS BEEN SHOWN TO REDUCE THE SOMA SIZE OF VTA DOPAMINE NEURONS AND DECREASE DOPAMINE OUTPUT IN THE NAC. IN ADDITION, A RECENT STUDY IN OUR LAB FOUND DOWNREGULATION OF IMPORTANT GENES FOR VTA DOPAMINE NEURON MATURATION AND AXONAL GUIDANCE IN THE VTA OF JUVENILE MICE PERINATALLY EXPOSED TO FENTANYL (PFE), A HIGHLY POTENT OPIOID, COMPARED TO CONTROLS. PRELIMINARY DATA FROM OUR LAB INDICATES THAT PFE MICE EXHIBIT REDUCED SOMA SIZE, MOTIVATION AS INDICATED BY ACTIVE LEVER PRESSING IN AN OPERANT TASK AND CUE EVOKED DOPAMINE SIGNALING COMPARED TO CONTROLS. THUS, I HYPOTHESIZE THAT PERINATAL FENTANYL EXPOSURE WILL LEAD TO REDUCED SOMA SIZE IN VTA DOPAMINE NEURONS AND THEIR PROPER AXONAL TARGETING, ALONG WITH DECREASED DOPAMINE RELEASE AND MOTIVATION IN ADULTHOOD. FIRST, I WILL USE DIFFERENTIAL GENE EXPRESSION AND MORPHOLOGICAL ANALYSIS ACROSS MULTIPLE DEVELOPMENTAL TIMEPOINTS TO UNDERSTAND THE TRANSCRIPTIONAL AND CIRCUIT LEVEL IMPACT OF PERINATAL FENTANYL EXPOSURE ON THE DEVELOPING MESOLIMBIC DOPAMINE PATHWAY. SECOND, I WILL USE FIBER PHOTOMETRIC RECORDING OF DOPAMINE DURING AN OPERANT BEHAVIORAL TASK TO INVESTIGATE HOW PERINATAL FENTANYL EXPOSURE AFFECTS DOPAMINE SIGNALING IN THE NAC AND MOTIVATION IN ADULTHOOD. THROUGH THESE EXPERIMENTS, I AIM TO UNCOVER THE IMPACT OF PERINATAL FENTANYL EXPOSURE ON THE DEVELOPMENT OF THE MESOLIMBIC DOPAMINE PATHWAY AND ITS FUNCTION IN ADULTHOOD.

Posted 12/12/24, 12:00 AM